Abstract
Objective To evaluate the difference of clinical efficacy of peramivir alone and peramivir combined with immunomodulators (either ribonucleic acid or thymopetidum) in the treatment of severe influenza A with primary viral pneumonia. Methods A retrospective analysis was applied to 45 patients who were diagnosed with severe influenza A with primary viral pneumonia in our hospital from December 2017 to March 2018. The cases were divided into three groups: the peramivir group, the peramivir combined with ribonucleic acid group, and the peramivir combined with thymopetidum group. Results The duration of viral nucleic acid positivity in the peramivir group, the peramivir combined with ribonucleic acid group, and the peramivir combined with thymopetidum group was 6.13 ± 2.06, 6.53 ± 2.72, and 6.10 ± 1.37 days, respectively. The remission time of the clinical symptoms of the peramivir group, the peramivir combined with ribonucleic acid group, and the peramivir combined with thymopetidum group was 8.06 ± 2.73, 7.94 ± 2.89, and 7.67 ± 1.58 days, respectively. Comparisons between the peramivir group and the peramivir combined with ribonucleic acid group or the peramivir combined with thymopetidum group revealed no significant differences in the duration of virus nucleic acid positivity, remission time of clinical symptoms, time to fever alleviation, and time to cough alleviation. Conclusions There is no observed benefit in the addition of ribonucleic acid or thymopetidum when peramivir sodium chloride injection is used in the treatment of severe influenza A with primary viral pneumonia. This trial is registered with ChiCTR1800019417.
Highlights
Influenza is an acute respiratory disease caused by the influenza virus
It may be that clinicians believe immunomodulators can help alleviate influenza symptoms by improving immunity of patients. is finding has attracted our attention, so the purpose of this study is to determine whether it is meaningful in the addition of ribonucleic acid or thymopetidum when peramivir sodium chloride injection is used in the treatment of severe influenza A with primary viral pneumonia
Forty-five hospitalized patients with severe influenza A complicated with primary viral pneumonia admitted to our hospital from December 2017 to March 2018 were selected according to “ e Influenza Diagnosis and Treatment Plan” issued by China in 2018. e inclusion criteria were as follows: (1) diagnosed as severe influenza A with primary viral pneumonia and (2) more than 18 years old, regardless of sex. e exclusion criteria were as follows: (1) vaccinated for influenza within the past six months (2) taking M2 channel blockers and neuraminidase inhibitors within the past month
Summary
Influenza is an acute respiratory disease caused by the influenza virus. Due to its strong infectivity and rapid transmission, influenza has broken out in the world for many times which seriously affected the health of people in various countries and caused immeasurable economic losses [1]. Influenza is mostly selflimited and is usually accompanied by fever, shivering, headache, myalgia, and so on. Some people such as the elderly, young children, and pregnant and lying-in women can develop into severe cases or even deaths because these populations are prone to complications including pneumonia, nervous system injury, and cardiac damage [2,3,4]. Ere are currently two categories of anti-influenza drugs. Category I are M2 ion channel blockers, and the main representative drugs are amantadine and rimantadine. Because of the high variability of influenza viruses, the resistance to M2 ion channel blockers has been high
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
